https://european-biotechnology.net/wp-content/uploads/2025/09/BIONTECH-HQ_393139602_Zb0h3vxEfpoM8LCZnO6asKBbaVrnKYhj-e1757228010811.jpg
563
1000
Thomas Gabrielczyk
/wp-content/uploads/2019/12/ebn-1-300x135.png
Thomas Gabrielczyk 2025-09-07 06:54:45 2025-09-12 10:02:02 BioNTech‘s breast cancer ADC outperforms Roche’s Kadcyla
https://european-biotechnology.net/wp-content/uploads/2025/09/Blackmint-Studio_1390096280_U26uHM9LFjqU55doX7W4iHtws8esSYLR.jpg
240
429
Thomas Gabrielczyk
/wp-content/uploads/2019/12/ebn-1-300x135.png
Thomas Gabrielczyk 2025-09-07 04:53:22 2025-09-12 10:02:02 Alt protein: EASAC sees immediate need for action
https://european-biotechnology.net/wp-content/uploads/2025/09/MRM-Health_287620039_HOUCde1qR0jiIIPYUSaejdsrkISIIa3P.jpg
750
1000
Thomas Gabrielczyk
/wp-content/uploads/2019/12/ebn-1-300x135.png
Thomas Gabrielczyk 2025-09-04 08:14:07 2025-09-12 10:02:02 Microbiome play MRM Health NV raises €55m in Series B
https://european-biotechnology.net/wp-content/uploads/2025/09/Lewy_Body_alphaSynuclein-e1756879718600.jpg
355
631
Thomas Gabrielczyk
/wp-content/uploads/2019/12/ebn-1-300x135.png
Thomas Gabrielczyk 2025-09-03 09:06:55 2025-09-12 10:02:02 Novartis invests US$200min lacklustre Parkinson’s target
https://european-biotechnology.net/wp-content/uploads/2025/09/Cytokinetics_Headquarters-e1756871185507-1030x580-1.jpg
580
1030
Thomas Gabrielczyk
/wp-content/uploads/2019/12/ebn-1-300x135.png
Thomas Gabrielczyk 2025-09-03 03:48:11 2025-09-12 10:02:02 Cytokinetics’ Aficamten with breakthrough Phase III results
https://european-biotechnology.net/wp-content/uploads/2025/09/Polpharma-Biologics-HQ-in-Gdansk-1-2-1-e1756822843167.jpg
451
800
Thomas Gabrielczyk
/wp-content/uploads/2019/12/ebn-1-300x135.png
Thomas Gabrielczyk 2025-09-02 14:29:11 2025-09-12 10:02:02 Polpharma Biologics secures distribution of upcoming biosimilars
https://european-biotechnology.net/wp-content/uploads/2025/09/Genetech_320984427_b8PYYp7YaXx5WBi6WwRXFIg8OupDixUA-e1756802020857.jpg
563
1000
Thomas Gabrielczyk
/wp-content/uploads/2019/12/ebn-1-300x135.png
Thomas Gabrielczyk 2025-09-02 08:37:03 2025-09-12 10:02:02 Genentech inks US$400m IBD deal with OMass Therapeutics
https://european-biotechnology.net/wp-content/uploads/2025/09/Sanofi_1090062434_e0WmVrZU84Vl6P9grrRF5Cmpr0yUupgT-e1756740428940.jpg
563
1000
Thomas Gabrielczyk
/wp-content/uploads/2019/12/ebn-1-300x135.png
Thomas Gabrielczyk 2025-09-01 15:27:51 2025-09-01 15:27:51 Sanofi receives US approval for oral ITP blockbuster
https://european-biotechnology.net/wp-content/uploads/2025/08/matt_cooper_1x-e1756455430543.jpg
270
480
Thomas Gabrielczyk
/wp-content/uploads/2019/12/ebn-1-300x135.png
Thomas Gabrielczyk 2025-08-29 08:19:51 2025-08-29 08:19:51 SitalaBio pays US$670m for Fosun inflammation blocker
https://european-biotechnology.net/wp-content/uploads/2025/08/Lilly-oral-GLP1_1509780785_BFQ4BXGNxP5LkXc8MnrqHsMZUC0tHA45-e1756277416706.jpg
563
1000
Thomas Gabrielczyk
/wp-content/uploads/2019/12/ebn-1-300x135.png
Thomas Gabrielczyk 2025-08-27 06:53:29 2025-08-27 06:53:29 Lilly’s weight loss pill orforglipron meets primary Phase III endpoint
Scroll to top
Scroll to top
Scroll to top
